Anti-IL2 antibodies

US7964707B2 · kind B2 · utility

Assignee

• Micromet AG · DE

Inventors

• Patrick Bauerle · Gauting, DE
• John Lumsden · Birkenfeld, DE
• Stefan Pflanz · Redwood City, US
• Tobias Raum · Munich, DE
• Jörg Volkland · Schwanau, DE

Key dates

• Filing date: May 31, 2006
• Grant date: Jun 21, 2011
• Expiry date: Jul 3, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.